Application of mogroside IIIA1 and salt or carrier thereof in preparation of product for preventing and treating osteoporosis

By using rohanfen saponin IIIA1 and its salt or carrier, it promotes osteoblast differentiation and improves bone density, solving the problem of side effects of existing osteoporosis treatment drugs, and providing a safe and effective novel treatment method.

CN119564711APending Publication Date: 2025-03-07SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411721052.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-28
Publication Date
2025-03-07

AI Technical Summary

Technical Problem

Existing osteoporosis treatment drugs have side effects and lack new safe and effective treatment methods.

Method used

Products for the prevention and/or treatment of osteoporosis are prepared using rohanfrosaponin IIIA1 and its pharmaceutically acceptable salts or carriers, by promoting the differentiation of osteoblasts, increasing bone metabolism levels, improving femoral calcium content and bone density.

Benefits of technology

Rohanfen saponin IIIA1 significantly increased the alkaline phosphatase (ALP) content of osteoblasts, promoted the differentiation of osteoblasts, and significantly improved bone density and calcium content in the mouse model of ovariectomy, providing a new and safer approach to treat osteoporosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005158046760000021
    Figure BDA0005158046760000021
  • Figure BDA0005158046760000121
    Figure BDA0005158046760000121
  • Figure BDA0005158046760000131
    Figure BDA0005158046760000131
Patent Text Reader

Abstract

The invention provides application of mogroside IIIA1 and salt or carrier thereof in preparation of products for preventing and treating osteoporosis, and belongs to the technical field of medical application. The application proves that the mogroside IIIA1 can promote osteoblast differentiation and improve the calcium content and bone mineral density of the thighbone of OVX mice, and has good application prospects in clinical treatment and promotion of osteogenesis and prevention and treatment of osteoporosis.
Need to check novelty before this filing date? Find Prior Art